Treatment for paediatric ABCA3‐related ILD traditionally involves immunomodulatory drugs, which have been shown to provide initial improvements in FVC in adult patients, but minimal sustained benefit [16]. This evidence concerns the gene ABCA3 and interstitial lung disease.